Carregant...
Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives
Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Despite substantial in vitro cytotoxicity, response rates in early clinical trials with 4-HPR have been less than anticipated, likely due to the low bioavailability of the initial oral capsule formulation....
Guardat en:
| Publicat a: | Exp Biol Med (Maywood) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5478002/ https://ncbi.nlm.nih.gov/pubmed/28429653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1535370217706952 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|